A Post Marketing Observational Study (PMOS) of the Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biological Disease Modifying Anti-rheumatic Drugs (BDMARDs) Over 1 Year

2014-08-27 03:15:18 | BioPortfolio


The aim of this PMOS is to obtain further data on long-term safety, efficacy and the evaluation of quality of life outcomes of the HUMIRA-Pen in routine clinical use in patients with Moderate to Severe Chronic Plaque Psoriasis after unsustainable clinical response to other biological disease modifying anti-rheumatic drugs (BDMARDs). There are no data so far, showing the effects of switching from other BDMARDs to Humira in patients with Moderate to Severe Chronic Plaque Psoriasis. This study is to evaluate the long-term effectiveness of Humira in patients with moderate to severe chronic plaque psoriasis - by using the PASI - in patients who are pre-treated with efalizumab, infliximab or etanercept and who either never achieved satisfactory response, achieved satisfactory response initially, but lost it over time, discontinued treatment due to intolerance/side effect(s), or other reasons for example after regular stop of etanercept.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Moderate to Severe Plaque Psoriasis


Site Reference ID/Investigator# 27435


Active, not recruiting



Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:15:18-0400

Clinical Trials [2121 Associated Clinical Trials listed on BioPortfolio]

A Registry of Patients With Moderate to Severe Plaque Psoriasis

The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe c...

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with ...

A Study Evaluating The Efficacy And Safety oO CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of tre...

Open Label Continuation Study in Moderate to Severe Psoriasis

Long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.

PubMed Articles [7238 Associated PubMed Articles listed on BioPortfolio]

Comprehensive Long-Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis.

Adalimumab (Humira ; AbbVie Inc., USA) is a fully human monoclonal antibody specific for tumour necrosis factor-α approved to treat adults with moderate-to-severe chronic plaque psoriasis.

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials.

Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibi...

Therapeutic equivalence of two formulations of calcipotriol-betamethasone ointment: a multi-centre, randomized, double-blind study in adult patients with chronic plaque psoriasis.

Topical agents are the first-line therapy for psoriasis and treatment of choice for mild to moderate chronic plaque psoriasis. Patients with severe psoriasis often use topical therapies at least for s...

Long-Term Optimization of Outcomes With Flexible Adalimumab Dosing in Patients With Moderate to Severe Plaque Psoriasis.

The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may ...

Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials.

Short-term IL-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears well-tolerated.

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.

Endovascular procedure in which atheromatous plaque is excised by a cutting or rotating catheter. It differs from balloon and laser angioplasty procedures which enlarge vessels by dilation but frequently do not remove much plaque. If the plaque is removed by surgical excision under general anesthesia rather than by an endovascular procedure through a catheter, it is called ENDARTERECTOMY.

An opioid analgesic used similarly to MORPHINE in the control of moderate to severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1097)

For-profit enterprise with relatively few to moderate number of employees and low to moderate volume of sales.

More From BioPortfolio on "A Post Marketing Observational Study (PMOS) of the Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biological Disease Modifying Anti-rheumatic Drugs (BDMARDs) Over 1 Year"

Quick Search


Relevant Topics

Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Searches Linking to this Trial